TScan (TCRX): Expected earnings per share growth for next year
The active development of solid tumor therapies through the search for specific antigens serves as the primary driver determining the projected change in earnings per share for TScan Therapeutics (TCRX) for the coming year. This chart illustrates expert expectations, where the current status is 24.60. Growth is supported by the TargetScan platform for precise cellular targeting, as well as the creation of publicly accessible donor T-cell banks for personalized medicine.
Analytical breakdowns and data insights for company TScan Therapeutics, Inc. (TCRX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization information:
- debt burden and liquidity indicators:
Total Debt to Capital TScan Therapeutics|TCRX - Long-Term Debt to Capital|Short-Term Debt to Equity TScan Therapeutics Inc|TCRX - Company Aggregate Debt|Debt to Book Value TScan Therapeutics|TCRX - Company Long-Term Loans and Borrowings|Company Current Liabilities TScan Therapeutics|Quick Ratio tscan.com
- net income and valuation ratios data:
TCRX - Final Profit|Projected Future Earnings TScan Therapeutics|TCRX - Market Cap to Earnings|Future Price to Earnings TScan Therapeutics Inc|TCRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TScan Therapeutics|TCRX - Operating profit EBITDA|Earnings per share for the last twelve months TScan Therapeutics|TCRX - Earnings per one share for the last 12 months|Quarterly EPS earnings growth tscan.com|TCRX - Earnings per share growth rate in current year|Expected earnings per share growth for next year TScan Therapeutics
General company analysis:TScan Therapeutics
TScan Therapeutics (TCRX) faces high toxicity risks in cell therapy trials and significant capital burn. Analyzing the forward-looking net income per share growth, we see a current value of 24.60. This metric aggregates expert expectations for future profitability, allowing investors to assess the pace of shifting market optimism and timely minimize the risks of a deep portfolio drawdown.
Competitor analysis for TScan Therapeutics
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Expected earnings per share growth for next year RVMD (Revolution Medicines)|Projected earnings per share increase next year AAPG|Net earnings per share growth forecast for next year CG Oncology CGON|Consensus forecast of earnings per share growth for next year UroGen Pharma Ltd (URGN)|Bicara Bio - Earnings growth forecast for next year|Personalis Genomics (PSNL) - Expected earnings per share growth for next year|ERAS: Earnings growth forecast for next year|delcath.com (DCTH) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics, Inc.|Projected earnings per share growth rate for next year AURA (Aura Biosciences Inc)|Expected earnings per share growth for next year CADL (Candel Therapeutics)|ARAY (Accuray, Inc.) - Expected earnings per share trend next year|SELLAS Life Sciences Group - Expected earnings per share growth for next year|Projected earnings per share increase next year ACTU (actuatetherapeutics.com)|Citius Oncology - Earnings growth forecast for next year|Expected earnings per share trend next year HURA (TuHURA Biosciences, Inc.)|TARA: Earnings growth forecast for next year|Expected net earnings per share growth next year Fate Pharma (FATE)|Net earnings per share growth forecast for next year Aadi Bioscience, Inc.|CSBR: Expected earnings per share trend next year|Earnings growth forecast for next year XBIT|Earnings growth forecast for next year cel-sci.com (CVM)|Net earnings per share growth forecast for next year OS Therapies Inc OSTX|RADX (radiopharmtheranostics.com) - Net earnings per share change forecast for next year|Artiva - Earnings growth forecast for next year|Expected net earnings per share growth next year Adlai Nortye Ltd.|VERU (Veru) - Expected earnings per share growth for next year|Tempest Therapeutics Inc (TPST) - Earnings growth forecast for next year|Expected earnings per share growth for next year XLO|RENB (Enochian BioSciences) - Projected earnings per share increase next year|Earnings growth forecast for next year MURA|Consensus forecast of earnings per share growth for next year kairospharma.com|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|GDTC - Expected earnings per share growth for next year|CRIS - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Apollomics, Inc. APLM|THAR (Tharimmune, Inc.) - Expected earnings per share growth for next year|ADVB: Projected earnings per share increase next year|GNPX (Genprex) - Earnings growth forecast for next year|Expected earnings per share growth for next year Calidi Bio (CLDI)|Net earnings per share growth forecast for next year Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - Expected earnings per share trend next year|Salarius Pharmaceuticals - Expected earnings per share growth for next year|PPBT: Projected earnings per share growth rate for next year|AON - Earnings growth forecast for next year|BeiGene Ltd. (BGNE) - Expected earnings per share growth for next year|CKPT: Earnings growth forecast for next year|elevationoncology.com (ELEV) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year iCAD Inc.|Projected earnings per share growth rate for next year IKNA (Ikena)|Earnings growth forecast for next year NTBL|Expected earnings per share growth for next year viracta.com VIRX|Earnings growth forecast for next year MOR (MorphoSys Corp)|NAYA Biosciences Corp (NAYA) - Expected net earnings per share growth next year|AAPGV - Net earnings per share growth forecast for next year
